Recurrent Pericarditis
Recurrent pericarditis is a challenging condition characterized by repeated episodes of pericardial inflammation. As a well-known CRO in the field of autoimmune diseases and inflammation, our company provides one-stop and customized recurrent pericarditis drug and therapy development solutions to help global pharmaceutical companies quickly complete research and development.
Introduction to Recurrent Pericarditis
Recurrent pericarditis refers to the presence of multiple episodes of pericardial inflammation after an initial episode of acute pericarditis. It is characterized by symptoms such as chest pain, pericardial friction rub, and sometimes, systemic manifestations like fever or elevated inflammatory markers. Recurrences can be spontaneous or triggered by various factors, ranging from infections to autoimmune processes. Immune dysregulation and aberrant cytokine signaling, particularly involving interleukin-1 (IL-1), have been implicated in the pathogenesis of recurrent pericarditis. IL-1 cytokines play a crucial role in initiating and sustaining the inflammatory response in the pericardium.
Fig.1 Therapeutics of recurrent pericarditis. (Andreis A., et al., 2021)
Drug Discovery and Development for Recurrent Pericarditis
First-line therapeutic often involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and high-dose acetylsalicylic acid (aspirin) to alleviate pericardial inflammation and provide symptomatic relief. Colchicine, a microtubule inhibitor, is frequently combined with NSAIDs or aspirin to prevent recurrences. Immunosuppressive agents such as azathioprine and intravenous immunoglobulins have shown promise in reducing recurrences and preventing corticosteroid dependence. Additionally, anti-IL-1 agents, including anakinra, rilonacept, and canakinumab, have demonstrated efficacy in managing refractory cases of recurrent pericarditis by specifically targeting the IL-1 pathway. Our therapy development services focus on the discovery and development of innovative therapeutics for recurrent pericarditis. If you would like to learn more about our therapy development services, please click on the link below.
Our Services
At our company, we offer a range of diagnostics and therapeutic development services to support researchers and pharmaceutical companies in their quest for improved therapeutics. Our most specialized diagnostics development services, including biomarker development and diagnostic kit development, enable accurate and early diagnosis of recurrent pericarditis.
NLRP3 Inflammasome
Activation Models
Our company provides an innovative mouse model development services, this model involves intrapericardial injection of zymosan A, an agonist of toll-like receptor-2 that activates the NLRP3 inflammasome. The injection leads to local inflammation, resulting in manifestations such as pericardial effusion, increased pericardial thickness, and elevated ASC expression.
Virus-Induced
Perimyocarditis Models
Chronic perimyocarditis represents a significant subset of pericarditis cases, characterized by persistent inflammation and subsequent fibrotic changes. At Our Company, we have developed a mouse model to simulate this chronic form of pericarditis. In this model, mice are injected with a specific virus, leading to histopathological changes over time.
Our company employs state-of-the-art techniques to isolate primary cells, ensuring their viability and functionality. These cells can include pericardial fibroblasts, immune cells, or endothelial cells, depending on the specific research objectives.
To develop an organoid model of recurrent pericarditis, we can differentiate stem cells into specific cell types found in the pericardium. These differentiated cells can then be combined and cultured in a three-dimensional matrix to form organoids that resemble the complexity of the pericardial tissue.
Through our preclinical research services, Our company supports the evaluation and validation of potential therapeutic interventions for recurrent pericarditis. Our team of experienced scientists and researchers conduct in vitro and in vivo studies to assess the pharmacokinetics, pharmacodynamics, and safety profiles of novel drug candidates. In addition to the aforementioned services and models, we also provide customized solutions and develop disease models that cater specifically to your unique needs. If our services have piqued your interest, please do not hesitate to contact us.
References
- Andreis A., et al. "Recurrent pericarditis: an update on diagnosis and management." Internal and Emergency Medicine 16 (2021): 551-558.
- Tombetti E., et al. "Novel pharmacotherapies for recurrent pericarditis: current options in 2020." Current Cardiology Reports 22 (2020): 1-11.